ArticleThe journal of prevention of Alzheimer's disease2021
Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force.
Article in The journal of prevention of Alzheimer's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review.Journal of medical Internet research · 2025Article
- A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease.NPJ digital medicine · 2025Article
- The AROMHA brain health test is a remote olfactory assessment to screen for cognitive impairment.Scientific reports · 2025Article
- Baseline Smartphone App Survey Return in the Electronic Framingham Heart Study Offspring and Omni 1 Study: eCohort Study.JMIR aging · 2024Article
- The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.NPJ digital medicine · 2024Article
- Social activities in multidomain dementia prevention interventions: insights from practice and a blueprint for the future.Frontiers in psychiatry · 2024Article
- Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia.Nature aging · 2023Review
- A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia.Cerebral circulation - cognition and behavior · 2023Review
- Conducting CNS trials during a public health emergency - Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper.Neuroscience applied · 2023Article
- Article
- Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.The journal of prevention of Alzheimer's disease · 2022Article
- A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty.Frontiers in digital health · 2021Article
- Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease.Frontiers in aging neuroscience · 2021Article
- Using Digital Speech Assessments to Detect Early Signs of Cognitive Impairment.Frontiers in digital health · 2021Article
- Automated detection of progressive speech changes in early Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2020 COVID-19 pandemic has disrupted Alzheimer's disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer's Disease (CTAD) Task Force met virtually in November 2020 to explore the opportunities and challenges associated with the use of digital technologies in AD clinical research. While recognizing the potential of digital tools to accelerate clinical trials, improve the engagement of diverse populations, capture clinically meaningful data, and lower costs, questions remain regarding the stability, validity, generalizability, and reproducibility of digital data. Substantial concerns also exist regarding regulatory acceptance and privacy. Nonetheless, the Task Force supported further exploration of digital technologies through collaboration and data sharing, noting the need for standardization of digital readouts. They also concluded that while it may be premature to employ remote assessments for trials of novel experimental medications, remote studies of non-invasive, multi-domain approaches may be feasible at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.